FindTrial
Sign In

Differentiation of Progression from Treatment Effects in High-Grade Gliomas: a Prospective Multicenter Clinical Trial with Multimodality MR Imaging

Differentiation of Progression from Treatment Effects in High-Grade Gliomas: a Prospective Multicenter Clinical Trial with Multimodality MR Imaging

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-DDD-17010744
Enrollment
Unknown
Registered
2017-02-27
Start date
2016-05-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioma

Interventions

Gold Standard:Use long-term clinical follow-up results or pathology as gold standard. Within 12 weeks after concurrent chemoradiotherapy was completed, the progress of disease can be diagnosed as foll
B. histologically proven disease.
Index test:Ktrans,&#32
Kep,&#32
Ve,&#32
Vp,&#32
ADC,&#32
D,&#32
D*,&#32
f,&#32
FA,&#32
MK,&#32
CBF

Sponsors

Jinling Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients with high-grade gliomas confirmed by pathology and have not been treated with concurrent chemoradiotherapy; 2. Written informed consent is abtained; 3. Aged between 18~80 years old.

Exclusion criteria

Exclusion criteria: 1. Patients not suitable for enhanced MRI scanning of patients; 2. Patients who have not finished follow-up concurrent chemoradiotherapy or MR scanning

Design outcomes

Primary

MeasureTime frame
Ktrans;ADC;CBF;—

Countries

China

Contacts

Public ContactLu Guangming

Jinling Hospital

cjr.luguangming@vip.163.com+86 13951608346

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026